Search

Your search keyword '"Kallieri Maria"' showing total 134 results
Start Over Author "Kallieri Maria"
134 results on '"Kallieri Maria"'

1. SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics

Author

Papaioannou, Andriana I., Fouka, Evangelia, Tzanakis, Nikolaos, Antoniou, Katerina, Samitas, Konstantinos, Zervas, Eleftherios, Kostikas, Konstantinos, Bartziokas, Konstantinos, Porpodis, Konstantinos, Papakosta, Despoina, Tzouvelekis, Argyris, Gerogianni, Irini, Kotsiou, Ourania, Makris, Michael, Rovina, Nikoletta, Vlachou, Garyfallia, Markatos, Miltiadis, Vittorakis, Stelios, Katsoulis, Konstantinos, Papanikolaou, Ilias, Afthinos, Andreas, Katsaounou, Paraskevi, Steiropoulos, Paschalis, Latsios, Dimitrios, Dimakou, Katerina, Koukidou, Sofia, Hillas, Georgios, Tryfon, Stavros, Kallieri, Maria, Georgopoulou, Athina, Avarlis, Pantelis, Bakakos, Petros, Markopoulou, Katerina, Gaki, Eleni, Paspala, Asimina, Kyriakaki, Zacharoula, Gourgoulianis, Konstantinos I., Papiris, Spyridon, and Loukides, Stelios

Published
2022
Full Text
View/download PDF

2. Long-Term Lung Sequelae in Survivors of Severe/Critical COVID-19 Pneumonia: The "Non-Steroid", "Non-Interventional" Approach.

Author

Antonogiannaki, Elvira-Markela, Grigoropoulos, Ioannis, Manali, Effrosyni D., Thomas, Konstantinos, Kallieri, Maria, Alexopoulou, Panagiota, Papaioannou, Andriana I., Prountzos, Spyridon, Karachaliou, Anastasia, Kontopoulou, Christina, Karageorgou, Vagia, Lampadakis, Stefanos, Blizou, Myrto, Tomos, Ioannis, Grigoropoulou, Sotiria, Kavatha, Dimitra, Loukides, Stelios, Antoniadou, Anastasia, and Papiris, Spyros A.

Subjects
INTERSTITIAL lung diseases, PULMONARY fibrosis, COMPUTED tomography, HOSPITAL admission & discharge, MEDICAL research
Abstract

Introduction: Long-term lung sequelae in severe COVID-19 survivors, as well as their treatment, are poorly described in the current literature. Objective: To investigate lung fibrotic sequelae in survivors of severe/critical COVID-19 pneumonia and their fate according to a "non-interventional" approach. Methods: Prospective study of the above COVID-19 survivors after hospital discharge from March 2020 to October 2022. Re-evaluation lasted 3–12 months and included chest HRCT, PFTs, dyspnea, and overall health evaluation by modified Medical Research Council (mMRC) and St. George's Respiratory Questionnaire (SGRQ), respectively. Results: In this study, 198 patients (61.1% male) with a median age of 57 years (IQR 49–66). After 3 months, 187 (94.4%) patients were assessed; after 6 months, 82 (41.1%) patients were assessed; and after 12 months, 16 (8%) patients were assessed. At each time point, a significant reduction was observed in the extent of COVID-19-associated opacities (p < 0.001 and p = 0.002) and of parenchymal bands (p = 0.014 and p = 0.025). Persisting fibrotic-like changes were observed in 18 (9%) patients (apical findings in 2 patients, fibrotic non-specific interstitial pneumonia-like changes in 14 patients, minimal fibrotic changes in 2 patients). At 3 months, the predicted median FVC% was 93% (80–100%) and the predicted DLCO% was 65% (58–78%) with a statistically significant improvement at 6 months in both (p = 0.001). Moreover, 81.1% had mMRC ≤ 1 and the median SGRQ was 11.65 [0–24.3] with a significant reduction at 6 months in both dyspnea (p < 0.001) and SGRQ (p = 0.027) persisting at 12 months. Conclusions: This prospective study, including only survivors of severe/critical COVID-19 pneumonia, documented the significant improvement in all imaging, functional, and clinical parameters by applying the "non-interventional" approach. These data do not indicate any post-COVID-19 severe/critical pneumonia and "epidemic of widespread pulmonary fibrosis". [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

3. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma

Author

Porsbjerg, Celeste M., Menzies-Gow, Andrew N., Tran, Trung N., Murray, Ruth B., Unni, Bindhu, Audrey Ang, Shi Ling, Alacqua, Marianna, Al-Ahmad, Mona, Al-Lehebi, Riyad, Altraja, Alan, Belevskiy, Andrey S., Björnsdóttir, Unnur S., Bourdin, Arnaud, Busby, John, Canonica, G. Walter, Christoff, George C., Cosio, Borja G., Costello, Richard W., FitzGerald, J. Mark, Fonseca, João A., Hansen, Susanne, Heaney, Liam G., Heffler, Enrico, Hew, Mark, Iwanaga, Takashi, Jackson, David J., Kocks, Janwillem W.H., Kallieri, Maria, Bruce Ko, Hsin-Kuo, Koh, Mariko Siyue, Larenas-Linnemann, Désirée, Lehtimäki, Lauri A., Loukides, Stelios, Lugogo, Njira, Maspero, Jorge, Papaioannou, Andriana I., Perez-de-Llano, Luis, Pitrez, Paulo Márcio, Popov, Todor A., Rasmussen, Linda M., Rhee, Chin Kook, Sadatsafavi, Mohsen, Schmid, Johannes, Siddiqui, Salman, Taillé, Camille, Taube, Christian, Torres-Duque, Carlos A., Ulrik, Charlotte, Upham, John W., Wang, Eileen, Wechsler, Michael E., Bulathsinhala, Lakmini, Carter, Victoria, Chaudhry, Isha, Eleangovan, Neva, Hosseini, Naeimeh, Rowlands, Mari-Anne, Price, David B., and van Boven, Job F.M.

Published
2022
Full Text
View/download PDF

4. Effects of menopause and fat mass in asthmatic inflammation.

Author

Papaporfyriou, Anastasia, Bartziokas, Kostas, Papachatzopoulou, Eftychia, Grapatsas, Kostas, Kallieri, Maria, Spathis, Aris, Steiropoulos, Paschalis, Bakakos, Petros, Papiris, Spyros, Loukides, Stelios, and Papaioannou, Andriana I.

Subjects
OBESITY in women, SEX hormones, ASTHMATICS, ESTRONE, POSTMENOPAUSE
Abstract

Introduction: Female hormones and obesity have an impact on women with asthma. We aimed to describe how these components affect asthma inflammatory processes. Methods: Sex hormones [FSH, LH, estradiol (E2), estrone (E1), testosterone and Δ4 androstenedione (A4)] and serum IL1β, IL13, IL17a, IL-5, IL6, TNF-a were measured from 11 to18 pre- and postmenopausal women with asthma. Results: Premenopausal normal weight women revealed higher levels of IL5 and IL17a than obese women on both days of the menstrual cycle (IL5: D1: 6.4 vs 1.4 pg/ml, p =.036 and D14: 3 vs 1.4 pg/ml, p =.045 and IL17a: D1: 13.7 pg/ml vs 10.6 pg/ml and D14: 12.4 pg/ml vs 10.6 pg/ml, p =.009, respectively). In premenopausal women on D1, Δ4 Androstenedione was positively correlated with IL1β (p =.016, r = 0.733), whereas on D14, Estradiol with IL1β (p =.009, r = −.768) and TNF-a with Testosterone (p =.004, r = −0.816), and Δ4 Androstenedione (p =.002, r = −0.841) negatively. In postmenopausal women, TNF-a was negatively associated with FSH (p =.004, r = −0.638), but positively with Testosterone (p =.025, r = 0.526) and IL10 also positively with Estradiol (p =.007, r = 0.610). Conclusion: Obesity shows a protective role in asthma through the suppression of IL5 and IL17. Estrogens seem to inhibit Th1 and Th2 inflammation, while androgens have a dual role with negative and positive correlations with neutrophilic biomarkers. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Sensitization to Staphylococcus Enterotoxin: Relationship with Aspects of Disease Severity.

Author

Schoini, Pinelopi, Apollonatou, Vasiliki, Kallieri, Maria, Blizou, Myrto, Sfika, Maria, Koufopoulos, Nektarios, Pouliakis, Abraham, Liatsis, Emmanouil, Foukas, Periklis, Bakakos, Petros, and Loukides, Stelios

Subjects
ASTHMATICS, IMMUNOGLOBULIN E, STAPHYLOCOCCUS aureus, SMOOTH muscle, SEROCONVERSION
Abstract

Background/Objective: Sensitization to specific IgE Staphylococcus aureus enterotoxins (SEs) is associated with an increased risk for severe asthma development. Limited data exist regarding the association of seropositivity for specific IgE SEs and the different aspects of severe asthma. We aimed to determine whether the presence of SEs is associated with asthma-related parameters such as inflammatory cells in the airways, features of airway remodeling, and other variables relating to asthma assessment and severity. Methods: Fifty patients with severe asthma were recruited in the study. Demographics, comorbidities, asthma duration, and asthma medication were recorded by treating physicians. Specific IgE SE measurement, lung function, atopic status, asthma control test (ACT), sputum induction, bronchoscopy with BAL, and indices of airway remodeling were also assessed. Results: Twelve patients were positive to enterotoxin sensitization. Patients seropositive to specific IgE SEs significantly differed in regard to FEV1% pred and FEV1/FVC ratio compared to seronegative ones. Analyzing the inflammatory variables obtained from induced sputum, BAL, and endobronchial biopsies, the only significant difference was that of smooth muscle area (SMA), which was greater in specific IgE SE seropositive patients. The multivariate linear regression analysis showed two significant associations of specific IgE SE seropositivity. We found a negative with FEV1% pred with beta standardized coefficient 95%CI −0.054 (−0.083, −0.031), p < 0.001, and a positive with SMA with beta standardized coefficient 95%CI 0.054 (0.081, 0.037), p < 0.001. Conclusions: Seropositivity to specific IgE SEs in severe asthma is associated with more severe airflow limitation, obstruction, and upregulation in SMA, indicating a possible role in the remodeling process. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Switching from omalizumab to mepolizumab in severe asthmatics: A post hoc analysis of the RELight study

Author

Kallieri, Maria, primary, Papaioannou, Andriana I., additional, Zervas, Eleftherios, additional, Fouka, Evangelia, additional, Porpodis, Konstantinos, additional, Hadji Mitrova, Marija, additional, Tzortzaki, Eleni, additional, Makris, Michael, additional, Ntakoula, Maria, additional, Lyberopoulos, Panagiotis, additional, Dimakou, Katerina, additional, Koukidou, Sofia, additional, Ampelioti, Sevasti, additional, Papaporfyriou, Anastasia, additional, Katsoulis, Konstantinos, additional, Kipourou, Maria, additional, Rovina, Nikoletta, additional, Antoniou, Katerina, additional, Vittorakis, Stylianos, additional, Bakakos, Petros, additional, Steiropoulos, Paschalis, additional, Markopoulou, Katerina, additional, Avarlis, Panteleimon, additional, Papanikolaou, Ιlias C., additional, Markatos, Miltiadis, additional, Gaki, Eleni, additional, Samitas, Konstantinos, additional, Glynos, Konstantinos, additional, Papiris, Spyros A., additional, Papakosta, Despoina, additional, Tzanakis, Nikolaos, additional, Gaga, Mina, additional, Kostikas, Konstantinos, additional, and Loukides, Stelios, additional

Published
2023
Full Text
View/download PDF

8. Switching from omalizumab to mepolizumab in severe asthmatics: A post hoc analysis of the RELight study.

Author

Kallieri, Maria, Papaioannou, Andriana I., Zervas, Eleftherios, Fouka, Evangelia, Porpodis, Konstantinos, Hadji Mitrova, Marija, Tzortzaki, Eleni, Makris, Michael, Ntakoula, Maria, Lyberopoulos, Panagiotis, Dimakou, Katerina, Koukidou, Sofia, Ampelioti, Sevasti, Papaporfyriou, Anastasia, Katsoulis, Konstantinos, Kipourou, Maria, Rovina, Nikoletta, Antoniou, Katerina, Vittorakis, Stylianos, and Bakakos, Petros

Subjects
*OMALIZUMAB, *ASTHMATICS, *BIOLOGICALS, *WHEEZE
Abstract

This article presents a post hoc analysis of the RELight study, which investigated the clinical benefit of switching from omalizumab to mepolizumab in patients with severe asthma. The study found that patients who switched to mepolizumab experienced a reduction in asthma exacerbations, improved asthma control, and a decrease in oral corticosteroid intake. These improvements were observed regardless of whether the patients had previously received omalizumab treatment. The findings suggest that switching therapies may be beneficial for patients with severe asthma who do not achieve optimal disease control. [Extracted from the article]

Published
2024
Full Text
View/download PDF

9. Patients Hospitalized for COVID-19 in the Periods of Delta and Omicron Variant Dominance in Greece: Determinants of Severity and Mortality

Author

Karageorgou, Vagia, primary, Papaioannou, Andriana I., additional, Kallieri, Maria, additional, Blizou, Myrto, additional, Lampadakis, Stefanos, additional, Sfika, Maria, additional, Krouskos, Antonios, additional, Papavasileiou, Vasileios, additional, Strakosha, Franceska, additional, Vandorou, Kalliopi Theoni, additional, Siozos, Pavlos, additional, Moustaka Christodoulou, Marina, additional, Kontonasiou, Georgia, additional, Apollonatou, Vasiliki, additional, Antonogiannaki, Elvira Markella, additional, Kyriakopoulos, Christos, additional, Aggelopoulou, Christina, additional, Chronis, Christos, additional, Kostikas, Konstantinos, additional, Koukaki, Evangelia, additional, Sotiropoulou, Zoi, additional, Athanasopoulou, Athanasia, additional, Bakakos, Petros, additional, Schoini, Pinelopi, additional, Alevrakis, Emmanouil, additional, Poupos, Sotirios, additional, Chondrou, Evangelia, additional, Tsoukalas, Dionisios, additional, Chronaiou, Alexia, additional, Tsoukalas, George, additional, Koukidou, Sofia, additional, Hillas, Georgios, additional, Dimakou, Katerina, additional, Roukas, Konstantinos, additional, Nakou, Ifigeneia, additional, Chloros, Diamantis, additional, Fouka, Evangelia, additional, Papiris, Spyros A., additional, and Loukides, Stelios, additional

Published
2023
Full Text
View/download PDF

10. Autoimmune Pulmonary Alveolar Proteinosis (aPAP) in Greece: 20 years in progress

Author

Papiris, Spyros A, primary, Kallieri, Maria, additional, Kolilekas, Lykourgos, additional, Papadaki, Georgia, additional, Verykakis, Emmanouil, additional, Kontonasiou, Georgia, additional, Papaioannou, Andriana I, additional, Bouros, Demosthenes, additional, Apollonatou, Vasiliki, additional, Antonogiannaki, Elvira-Markela, additional, Lyberopoulos, Panagiotis, additional, Roussakis, Nikolaos, additional, Douros, Konstantinos, additional, Schams, Andrea, additional, Griese, Matthias, additional, and Manali, Effrosyni D., additional

Published
2023
Full Text
View/download PDF

11. Comparison of patients hospitalized for COVID-19 in the periods of Delta and Omicron variants dominance in Greece

Author

Karageorgou, Vagia, primary, Papaioanou, Andriana I, additional, Kallieri, Maria, additional, Blizou, Myrto, additional, Lampadakis, Stefanos, additional, Sfika, Maria, additional, Krouskos, Antonios, additional, Papavasileiou, Vasileios, additional, Strakosha, Franceska, additional, Vandorou, Kalliopi Theoni, additional, Siozos, Pavlos, additional, Moustaka Christodoulou, Marina, additional, Kontonasiou, Georgia, additional, Apollonatou, Vasiliki, additional, Antonogiannaki, Elvira Markella, additional, Kyriakopoulos, Christos, additional, Aggelopoulou, Christina, additional, Chronis, Christos, additional, Kostikas, Konstantinos, additional, Koukaki, Evangelia, additional, Sotiropoulou, Zoi, additional, Athanasopoulou, Athanasia, additional, Bakakos, Petros, additional, Sxini, Pinelopi, additional, Alevrakis, Emmanouil, additional, Poupos, Sotirios, additional, Chondrou, Evangelia, additional, Tsoukalas, Dionisis, additional, Chronaiou, Alexia, additional, Tsoukalas, George, additional, Koukidou, Sofia, additional, Hillas, Georgios, additional, Dimakou, Katerina, additional, Roukas, Konstantinos, additional, Nakou, Ifigenia, additional, Chloros, Diamantis, additional, Fouka, Evangelia, additional, Papiris, Spyros A, additional, and Loukides, Stelios, additional

Published
2023
Full Text
View/download PDF

12. The clinical experience of patients with severe asthma and previous treatment with omalizumab, choosing mepolizumab in Greece.

Author

Kallieri, Maria, primary, Papaioannou, Andriana I., additional, Zervas, Eleftherios, additional, Fouka, Evangelia, additional, Porpodis, Konstantinos, additional, Hadji Mitrova, Marija, additional, Tzortzaki, Eleni, additional, Makris, Michael, additional, Ntakoula, Maria, additional, Lyberopoulos, Panagiotis, additional, Dimakou, Katerina, additional, Koukidou, Sofia, additional, Ampelioti, Sevasti, additional, Papaporfyriou, Anastasia, additional, Katsoulis, Konstantinos, additional, Kipourou, Maria, additional, Rovina, Nikoletta, additional, Antoniou, Katerina, additional, Vittorakis, Stylianos, additional, Bakakos, Petros, additional, Steiropoulos, Paschalis, additional, Markopoulou, Katerina, additional, Avarlis, Panteleimon, additional, Papanikolaou, Ιlias C., additional, Markatos, Miltiadis, additional, Gaki, Eleni, additional, Samitas, Konstantinos, additional, Glynos, Konstantinos, additional, Papiris, Spyros A., additional, Papakosta, Despoina, additional, Tzanakis, Nikolaos, additional, Gaga, Mina, additional, Kostikas, Konstantinos, additional, and Loukides, Stelios, additional

Published
2023
Full Text
View/download PDF

13. This title is unavailable for guests, please login to see more information.

Author

Kallieri Maria and Kallieri Maria

Abstract

PROTOCOL I Introduction: Mepolizumab is a targeted, humanized anti–IL-5 monoclonal antibody that prevents IL-5 from binding to its receptor on eosinophils, and selectively inhibits eosinophilic inflammation and is approved for the treatment of severe eosinophilic asthma. Aims / objectives: To determine the 2-year clinical experience, effectiveness, and safety of mepolizumab treatment for patients with severe eosinophilic asthma, in referral centers in Greece. Methods: This is a prospective, multicenter, observational study, which was conducted in 22 different centers in Greece. The primary endpoint was to assess clinically significant asthma exacerbations (CSE) after 12 and 24 months of treatment respectively. Results: 169 patients were eligible for the study (28% male, mean±SD age 57.7±12.6). 134 (79.3%) completed the 24-month follow -up. After a 2-year treatment there was 71.8% reduction (p<0.001) of CSE. At 24 months, there was a significant improvement in the ACT score from 15.2±4.5 to 21.8±3.1, and lung function as assessed by the increase in FEV1, from 1.87±0.7 to 2.2±0.8 L, p<0.001. OCS maintenance was significantly reduced from 10.6±7.5 mg/day to 1.7±3mg/day, p<0.001 at 24 months. Of note, 71% of those treated with OCS at baseline discontinued OCS altogether. According to the pre-defined Response Definition 1, 83.8% of patients were responders at 24 months and 19.6% were super-responders, and according to the Response Definition 2, 93.1% were responders at 24 months and 27.5% were super-responders. No significant safety issues were observed. Conclusions: In this observational study mepolizumab was associated with significant reductions in the annual rate of exacerbations and maintenance OCS use, and improvement in asthma control and lung function that were maintained after two years of treatment. PROTOCOL II Objectives: Omalizumab is a recombinant humanized IgG1 monoclonal anti-IgE antibody, used for the treatment of severe refractory allergic asthm

Published
2023

14. Φαινοτυπικός καθορισμός ασθενών με άσθμα και χρόνια αποφρακτική πνευμονοπάθεια

Author

Kallieri Maria

Subjects
Health Sciences, Επιστήμες Υγείας
Abstract

ΠΡΩΤΟΚΟΛΛΟ Ι Εισαγωγή: Η Μεπολιζουμάμπη είναι ένα εξανθρωποποιημένο μονοκλωνικό αντίσωμα έναντι της ιντερλευκίνης 5 (IL-5), που εμποδίζει την σύνδεση της με τον υποδοχέα της IL-5 στην επιφάνεια των ηωσινοφίλων, με αποτέλεσμα την εκλεκτική αναστολή της ηωσινοφιλικής φλεγμονής, ενώ αποτελεί εγκεκριμένη θεραπεία για το σοβαρό ηωσινοφιλικό άσθμα. Στόχος: Να περιγραφεί η διετής κλινική εμπειρία, η αποτελεσματικότητα και η ασφάλεια της θεραπείας με μεπολιζουμάμπη στη θεραπεία ασθενών με σοβαρό ανθιστάμενο στη θεραπεία ηωσινοφιλικό άσθμα, σε ειδικά κέντρα στην Ελλάδα. Μέθοδοι: Πρόκειται για μία προοπτική, πολυκεντρική, μη παρεμβατική μελέτη παρατήρησης που διεξήχθη σε 22 διαφορετικά κέντρα στην Ελλάδα. Κύριο καταληκτικό σημείο ήταν ο προσδιορισμός των κλινικά σημαντικών παροξύνσεων του άσθματος μετά από 12 και 24 μήνες θεραπείας, αντίστοιχα. Αποτελέσματα: 169 ασθενείς συμπεριλήφθηκαν στη μελέτη (28% άνδρες, μέση ± SD ηλικία 57.7±12.6). 134 (79.3%) ολοκλήρωσαν τους 24 μήνες παρατήρησης. Μετά από 2 χρόνια θεραπείας υπήρξε μείωση κατά 71.8% (p

Published
2023

15. Diffuse panniculitis in a teen male with ZZ alpha1-antitrypsin deficiency

Author

Papiris, Spyros A., primary, Parmaxidis, Anthimos, additional, Theotokoglou, Sofia, additional, Tsakiraki, Zoe, additional, Veith, Martina, additional, Panagiotou, Aikaterini, additional, Pappa, Vasiliki, additional, Kallieri, Maria, additional, Mornex, Jean-François, additional, Katoulis, Alexander C., additional, Haritos, Dionysios, additional, Panayiotides, Ioannis G., additional, and Manali, Effrosyni D., additional

Published
2023
Full Text
View/download PDF

16. Genetics in Idiopathic Pulmonary Fibrosis: A Clinical Perspective

Author

Papiris, Spyros A., primary, Kannengiesser, Caroline, additional, Borie, Raphael, additional, Kolilekas, Lykourgos, additional, Kallieri, Maria, additional, Apollonatou, Vasiliki, additional, Ba, Ibrahima, additional, Nathan, Nadia, additional, Bush, Andrew, additional, Griese, Matthias, additional, Dieude, Philippe, additional, Crestani, Bruno, additional, and Manali, Effrosyni D., additional

Published
2022
Full Text
View/download PDF

17. Sestrin 2 levels are associated with emphysematous phenotype of COPD

Author

Angelakis, Leonidas, primary, Papaioannou, Andriana I., additional, Papathanasiou, Evgenia, additional, Mazioti, Argiro, additional, Kallieri, Maria, additional, Papatheodorou, George, additional, Patentalakis, George, additional, Hillas, Georgios, additional, Papiris, Spyridon, additional, Koulouris, Nikolaos, additional, Loukides, Stelios, additional, and Bakakos, Petros, additional

Published
2022
Full Text
View/download PDF

18. COVID-19 in patients with pulmonary alveolar proteinosis: a European multicentre study

Author

Papiris, Spyros A., primary, Campo, Ilaria, additional, Mariani, Francesca, additional, Kallieri, Maria, additional, Kolilekas, Lykourgos, additional, Papaioannou, Andriana I., additional, Gonca Chousein, Efsun, additional, Cetinkaya, Erdogan, additional, Bonella, Francesco, additional, Borie, Raphael, additional, Kokosi, Maria, additional, Pickworth, Thomas, additional, Molina-Molina, Maria, additional, Gasa, Mercè, additional, Radzikowska, Elżbieta, additional, Fijolek, Justyna, additional, Jouneau, Stéphane, additional, Gomez, Emmanuel, additional, McCarthy, Cormac, additional, Bendstrup, Elisabeth, additional, Piotrowski, Wojciech J., additional, Pabary, Rishi, additional, Hadchouel, Alice, additional, Coolen-Allou, Nathalie, additional, Alfaro, Tiago, additional, Robalo Cordeiro, Carlos, additional, Antonogiannaki, Elvira-Markela, additional, Tomos, Ioannis P., additional, Papakosta, Despoina, additional, Kontakiotis, Theodoros, additional, Panagiotou, Panagiota, additional, Douros, Konstantinos, additional, Schams, Andrea, additional, Lettieri, Sara, additional, Papaevangelou, Vassiliki, additional, Kanaka-Gantenbein, Christina, additional, Karakatsani, Anna, additional, Loukides, Stelios, additional, Costabel, Ulrich, additional, Crestani, Bruno, additional, Morgan, Cliff, additional, Tazawa, Ryushi, additional, Bush, Andrew, additional, Griese, Matthias, additional, and Manali, Effrosyni D., additional

Published
2022
Full Text
View/download PDF

19. Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study

Author

Menzies-Gow, Andrew N. McBrien, Claire Unni, Bindhu and Porsbjerg, Celeste M. Al-Ahmad, Mona Ambrose, Christopher S. and Assing, Karin Dahl von Bulow, Anna Busby, John Cosio, Borja G. FitzGerald, J. Mark Gil, Esther Garcia Hansen, Susanne and aHeaney, Liam G. Hew, Mark Jackson, David J. Kallieri, Maria Loukides, Stelios Lugogo, Njira L. Papaioannou, I, Andriana Larenas-Linnemann, Desiree Moore, Wendy C. and Perez-de-Llano, Luis A. Rasmussen, Linda M. Schmid, Johannes M. and Siddiqui, Salman Alacqua, Marianna Tran, Trung N. Ulrik, Charlotte Suppli Upham, John W. Wang, Elleen Bulathsinhala, Lakmini Carter, Victoria A. Chaudhry, Isha Eleangovan, Neva and Murray, Ruth B. Price, Chris A. Price, David B. and Menzies-Gow, Andrew N. McBrien, Claire Unni, Bindhu and Porsbjerg, Celeste M. Al-Ahmad, Mona Ambrose, Christopher S. and Assing, Karin Dahl von Bulow, Anna Busby, John Cosio, Borja G. FitzGerald, J. Mark Gil, Esther Garcia Hansen, Susanne and aHeaney, Liam G. Hew, Mark Jackson, David J. Kallieri, Maria Loukides, Stelios Lugogo, Njira L. Papaioannou, I, Andriana Larenas-Linnemann, Desiree Moore, Wendy C. and Perez-de-Llano, Luis A. Rasmussen, Linda M. Schmid, Johannes M. and Siddiqui, Salman Alacqua, Marianna Tran, Trung N. Ulrik, Charlotte Suppli Upham, John W. Wang, Elleen Bulathsinhala, Lakmini Carter, Victoria A. Chaudhry, Isha Eleangovan, Neva and Murray, Ruth B. Price, Chris A. Price, David B.

Abstract

Introduction: International registries provide opportunities to describe use of biologics for treating severe asthma in current clinical practice. Our aims were to describe real-life global patterns of biologic use (continuation, switches, and discontinuations) for severe asthma, elucidate reasons underlying these patterns, and examine associated patient-level factors. Methods: This was a historical cohort study including adults with severe asthma enrolled into the International Severe Asthma Registry (ISAR; http://isaregistries.org, 2015-2020) or the CHRONICLE Study (2018-2020) and treated with a biologic. Eleven countries were included (Bulgaria, Canada, Denmark, Greece, Italy, Japan, Kuwait, South Korea, Spain, UK, and USA). Biologic utilization patterns were defined: 1) continuing initial biologic; 2) stopping biologic treatment; or 3) switching to another biologic. Reasons for discontinuation/switching were recorded and comparisons drawn between groups. Results: A total of 3531 patients were included. Omalizumab was the most common initial biologic in 2015 (88.2%) and benralizumab in 2019 (29.6%). Most patients (79%; 2791/3531) continued their first biologic; 10.2% (356/3531) stopped; 10.8% (384/3531) switched. The most frequent first switch was from omalizumab to an anti-IL-5/5R (49.6%; 187/377). The most common subsequent switch was from one anti-IL-5/5R to another (44.4%; 20/45). Insufficient efficacy and/or adverse effects were the most frequent reasons for stopping/switching. Patients who stopped/switched were more likely to have a higher baseline blood eosinophil count and exacerbation rate, lower lung function, and greater health care resource utilization. Conclusion: The description of real-life patterns of continuing, stopping, or switching biologics enhances our understanding of global biologic use. Prospective studies involving structured switching criteria could ascertain optimal strategies to identify patients who may benefit from switching.

Published
2022

20. Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study

Author

Menzies-Gow,Andrew N, McBrien,Claire, Unni,Bindhu, Porsbjerg,Celeste M, Al-Ahmad,Mona, Ambrose,Christopher S, Dahl Assing,Karin, von Bülow,Anna, Busby,John, Cosio,Borja G, FitzGerald,J Mark, Garcia Gil,Esther, Hansen,Susanne, Heaney,Liam G, Hew,Mark, Jackson,David J, Kallieri,Maria, Loukides,Stelios, Lugogo,Njira L, Papaioannou,Andriana I, Larenas-Linnemann,Désirée, Moore,Wendy C, Perez-de-Llano,Luis A, Rasmussen,Linda M, Schmid,Johannes M, Siddiqui,Salman, Alacqua,Marianna, Tran,Trung N, Suppli Ulrik,Charlotte, Upham,John W, Wang,Eileen, Bulathsinhala,Lakmini, Carter,Victoria A, Chaudhry,Isha, Eleangovan,Neva, Murray,Ruth B, Price,Chris A, Price,David B, Menzies-Gow,Andrew N, McBrien,Claire, Unni,Bindhu, Porsbjerg,Celeste M, Al-Ahmad,Mona, Ambrose,Christopher S, Dahl Assing,Karin, von Bülow,Anna, Busby,John, Cosio,Borja G, FitzGerald,J Mark, Garcia Gil,Esther, Hansen,Susanne, Heaney,Liam G, Hew,Mark, Jackson,David J, Kallieri,Maria, Loukides,Stelios, Lugogo,Njira L, Papaioannou,Andriana I, Larenas-Linnemann,Désirée, Moore,Wendy C, Perez-de-Llano,Luis A, Rasmussen,Linda M, Schmid,Johannes M, Siddiqui,Salman, Alacqua,Marianna, Tran,Trung N, Suppli Ulrik,Charlotte, Upham,John W, Wang,Eileen, Bulathsinhala,Lakmini, Carter,Victoria A, Chaudhry,Isha, Eleangovan,Neva, Murray,Ruth B, Price,Chris A, and Price,David B

Abstract

Andrew N Menzies-Gow,1 Claire McBrien,2 Bindhu Unni,3 Celeste M Porsbjerg,4 Mona Al-Ahmad,5 Christopher S Ambrose,6 Karin Dahl Assing,7 Anna von Bülow,4 John Busby,8 Borja G Cosio,9 J Mark FitzGerald,10 Esther Garcia Gil,11 Susanne Hansen,12 Liam G aHeaney,8 Mark Hew,13,14 David J Jackson,15,16 Maria Kallieri,17 Stelios Loukides,17 Njira L Lugogo,18 Andriana I Papaioannou,17 Désirée Larenas-Linnemann,19 Wendy C Moore,20 Luis A Perez-de-Llano,21 Linda M Rasmussen,22 Johannes M Schmid,23 Salman Siddiqui,24 Marianna Alacqua,25 Trung N Tran,6 Charlotte Suppli Ulrik,26 John W Upham,27 Eileen Wang,28,29 Lakmini Bulathsinhala,3,30 Victoria A Carter,3,30 Isha Chaudhry,3,30 Neva Eleangovan,3,30 Ruth B Murray,3,30 Chris A Price,3,30 David B Price3,30,31 1UK Severe Asthma Network and National Registry, Royal Brompton & Harefield Hospitals, London, UK; 2Kingston Hospital, London, UK; 3Observational and Pragmatic Research Institute, Singapore, Singapore; 4Respiratory Research Unit, Bispebjerg University Hospital, Copenhagen, Denmark; 5Al-Rashed Allergy Center, Ministry of Health, Microbiology Department, Faculty of Medicine, Kuwait University, Kuwait, Kuwait; 6AstraZeneca, Gaithersburg, MD, USA; 7Department of Respiratory Medicine, Aalborg University Hospital, Aalborg, Denmark; 8UK Severe Asthma Network and National Registry, Queen’s University Belfast, Belfast, Northern Ireland; 9Son Espases University Hospital-IdISBa-Ciberes, Mallorca, Spain; 10The Centre for Lung Health, Vancouver Coastal Health Research Institute, UBC, Vancouver, Canada; 11AstraZeneca, Barcelona, Spain; 12Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; 13Allergy, Asthma & Clinical Immunology Service, Alfred Health, Melbourne, Australia; 14Public Health and Preventive Medicine, Monash University, Melbourne, Australia; 15UK Severe Asthma Network andNational Registry, Guy’s and St Thomas’ NHS Trust, London, UK; 16School of Immunology &amp

Published
2022

21. Real World Biologic Use and Switch Patterns in Severe Asthma:Data from the International Severe Asthma Registry and the US CHRONICLE Study

Author

Menzies-Gow, Andrew N., McBrien, Claire, Unni, Bindhu, Porsbjerg, Celeste M., Al-Ahmad, Mona, Ambrose, Christopher S., Dahl Assing, Karin, von Bülow, Anna, Busby, John, Cosio, Borja G., Fitzgerald, J. Mark, Garcia Gil, Esther, Hansen, Susanne, Aheaney, Liam G., Hew, Mark, Jackson, David J., Kallieri, Maria, Loukides, Stelios, Lugogo, Njira L., Papaioannou, Andriana I., Larenas-Linnemann, Désirée, Moore, Wendy C., Perez-De-llano, Luis A., Rasmussen, Linda M., Schmid, Johannes M., Siddiqui, Salman, Alacqua, Marianna, Tran, Trung N., Suppli Ulrik, Charlotte, Upham, John W., Wang, Eileen, Bulathsinhala, Lakmini, Carter, Victoria A., Chaudhry, Isha, Eleangovan, Neva, Murray, Ruth B., Price, Chris A., Price, David B., Menzies-Gow, Andrew N., McBrien, Claire, Unni, Bindhu, Porsbjerg, Celeste M., Al-Ahmad, Mona, Ambrose, Christopher S., Dahl Assing, Karin, von Bülow, Anna, Busby, John, Cosio, Borja G., Fitzgerald, J. Mark, Garcia Gil, Esther, Hansen, Susanne, Aheaney, Liam G., Hew, Mark, Jackson, David J., Kallieri, Maria, Loukides, Stelios, Lugogo, Njira L., Papaioannou, Andriana I., Larenas-Linnemann, Désirée, Moore, Wendy C., Perez-De-llano, Luis A., Rasmussen, Linda M., Schmid, Johannes M., Siddiqui, Salman, Alacqua, Marianna, Tran, Trung N., Suppli Ulrik, Charlotte, Upham, John W., Wang, Eileen, Bulathsinhala, Lakmini, Carter, Victoria A., Chaudhry, Isha, Eleangovan, Neva, Murray, Ruth B., Price, Chris A., and Price, David B.

Abstract

Introduction: International registries provide opportunities to describe use of biologics for treating severe asthma in current clinical practice. Our aims were to describe real-life global patterns of biologic use (continuation, switches, and discontinuations) for severe asthma, elucidate reasons underlying these patterns, and examine associated patient-level factors. Methods: This was a historical cohort study including adults with severe asthma enrolled into the International Severe Asthma Registry (ISAR; http://isaregistries.org, 2015–2020) or the CHRONICLE Study (2018–2020) and treated with a biologic. Eleven countries were included (Bulgaria, Canada, Denmark, Greece, Italy, Japan, Kuwait, South Korea, Spain, UK, and USA). Biologic utilization patterns were defined: 1) continuing initial biologic; 2) stopping biologic treatment; or 3) switching to another biologic. Reasons for discontinuation/ switching were recorded and comparisons drawn between groups. Results: A total of 3531 patients were included. Omalizumab was the most common initial biologic in 2015 (88.2%) and benralizumab in 2019 (29.6%). Most patients (79%; 2791/3531) continued their first biologic; 10.2% (356/3531) stopped; 10.8% (384/3531) switched. The most frequent first switch was from omalizumab to an anti–IL-5/5R (49.6%; 187/377). The most common subsequent switch was from one anti–IL-5/5R to another (44.4%; 20/45). Insufficient efficacy and/or adverse effects were the most frequent reasons for stopping/switching. Patients who stopped/switched were more likely to have a higher baseline blood eosinophil count and exacerbation rate, lower lung function, and greater health care resource utilization. Conclusion: The description of real-life patterns of continuing, stopping, or switching biologics enhances our understanding of global biologic use. Prospective studies involving structured switching criteria could ascertain optimal strategies to identify patients who may benefit from switching.

Published
2022

22. RELIght: A two‐year REal‐LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: Evaluating the multiple components of response

Author

Kallieri, Maria, primary, Zervas, Eleftherios, additional, Fouka, Evangelia, additional, Porpodis, Konstantinos, additional, Mitrova, Marija Hadji, additional, Tzortzaki, Eleni, additional, Makris, Michael, additional, Ntakoula, Maria, additional, Papaioannou, Andriana I., additional, Lyberopoulos, Panagiotis, additional, Dimakou, Katerina, additional, Koukidou, Sofia, additional, Ampelioti, Sevasti, additional, Papaporfyriou, Anastasia, additional, Katsoulis, Konstantinos, additional, Kipourou, Maria, additional, Rovina, Nikoletta, additional, Antoniou, Katerina, additional, Vittorakis, Stylianos, additional, Bakakos, Petros, additional, Steiropoulos, Paschalis, additional, Markopoulou, Katerina, additional, Avarlis, Panteleimon, additional, Papanikolaou, Ιlias C., additional, Markatos, Miltiadis, additional, Gaki, Eleni, additional, Samitas, Konstantinos, additional, Glynos, Konstantinos, additional, Papiris, Spyros A., additional, Papakosta, Despoina, additional, Tzanakis, Nikolaos, additional, Gaga, Mina, additional, Kostikas, Konstantinos, additional, and Loukides, Stelios, additional

Published
2022
Full Text
View/download PDF

24. Epidemiological characteristics, clinical features and outcomes of patients with COVID-19 admitted to seven reference centers across Greece: An observational study during the fourth and fifth waves of the COVID-19 pandemic.

Author

Papaioannou, Ourania, Karampitsakos, Theodoros, Tsiri, Panagiota, Karageorgou, Vagia, Papaioannou, Andriana I., Kallieri, Maria, Blizou, Myrto, Lampadakis, Stefanos, Sfika, Maria, Krouskos, Antonios, Papavasileiou, Vasilis, Strakosha, Franceska, Vandorou, Kalliopi-Theoni, Siozos, Pavlos, Moustaka-Christodoulou, Marina, Kontonasiou, Georgia, Apollonatou, Vasiliki, Antonogiannaki, Elvira-Markella, Kyriakopoulos, Christos, and Aggelopoulou, Christina

Subjects
COVID-19, COVID-19 pandemic, NEUTROPHIL lymphocyte ratio, BLOOD cell count, COMPUTED tomography, H7N9 Influenza
Abstract

INTRODUCTION Epidemiological data from hospitalized patients with COVID-19 during the fourth and fifth waves of the pandemic have been published worldwide. METHODS This registry was an observational, prospective study conducted in seven reference hospitals across Greece. Maximum FiO2 during hospitalization and Charlson comorbidity index (CCI) on admission were correlated with disease severity, as well as radiological features, parameters of complete blood count, and d-dimer. RESULTS A total of 1019 patients were included in the analysis; 55.1% and 57.2% of patients were males and never smokers, respectively, with median age of 67 years (95% CI: 65.7-69.0). Patients with increased extent of consolidation and ground glass opacities in chest CT (>10-25%) exhibited more advanced disease compared to the low extent group (<10%) as indicated by both CCI on admission (3; 95% CI: 2-3 vs 2; 95% CI: 1-2, p=0.0002) and MaxFiO2 (0.40; 95% CI: 0.35-0.40 vs 0.28; 95% CI: 0.24-0.28, p<0.0001). Patients with high neutrophil to lymphocyte ratio (=4.42) exhibited more severe disease as indicated by significantly increased CCI on admission (4; 95% CI: 3 to 4 vs 3; 95% CI: 2-3, p<0.0001) and MaxFiO2 (0.35; 95% CI: 0.35-0.4 vs 0.28; 95% CI: 0.28-0.28, p<0.0001). Patients with elevated d-dimer (=0.74 µg/mL) displayed also advanced disease compared to the low d-dimer group (<0.74 µg/mL), as assessed by both CCI on admission (4; 95% CI: 4-4 vs 2; 95% CI: 2-2, p<0.0001) and MaxFiO2 (0.38; 95% CI: 0.35-0.40 vs 0.28; 95% CI: 0.28-0.28, p<0.0001). CONCLUSIONS We present the first observational study across Greece during the fourth and fifth waves of the COVID-19 pandemic. Extent of opacities in chest CT, neutrophil to lymphocyte ratio and d-dimer may represent reliable disease prognostic factors leading to timely therapeutic interventions. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. Autoimmune PAP (aPAP) in children

Author

Griese, Matthias, primary, Panagiotou, Panagiota, additional, Manali, Effrosyni D., additional, Stahl, Mirjam, additional, Schwerk, Nicolaus, additional, Costa, Vanessa, additional, Douros, Konstantinos, additional, Kallieri, Maria, additional, Urbantat, Ruth Maria, additional, von Bernuth, Horst, additional, Kolilekas, Lykourgos, additional, Morais, Lurdes, additional, Ramos, Ana, additional, Landwehr, Kerstin, additional, Knoflach, Katrin, additional, Gothe, Florian, additional, Reiter, Karl, additional, Papaevangelou, Vassiliki, additional, Kaditis, Athanasios G., additional, Kanaka-Gantenbein, Christina, additional, and Papiris, Spyros A., additional

Published
2022
Full Text
View/download PDF

26. Pulmonary hemorrhage in patients receiving anti-platelets- a case series and a suggested therapeutic algorithm

Author

Tomos, Ioannis, primary, Kallieri, Maria, additional, Papaioannou, Andriana I., additional, Stagaki, Eleni, additional, Raptakis, Thomas, additional, Karakatsani, Anna, additional, Korkonikitas, Panagiotis, additional, Manali, Effrosyni D., additional, Karageorgou, Vagia, additional, Mplizou, Myrto, additional, Vlami, Katerina, additional, Loukides, Stelios, additional, and Papiris, Spyros, additional

Published
2022
Full Text
View/download PDF

27. Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study

Author

Menzies-Gow, Andrew N, primary, McBrien, Claire, additional, Unni, Bindhu, additional, Porsbjerg, Celeste M, additional, Al-Ahmad, Mona, additional, Ambrose, Christopher S, additional, Dahl Assing, Karin, additional, von Bülow, Anna, additional, Busby, John, additional, Cosio, Borja G, additional, FitzGerald, J Mark, additional, Garcia Gil, Esther, additional, Hansen, Susanne, additional, Heaney, Liam G, additional, Hew, Mark, additional, Jackson, David J, additional, Kallieri, Maria, additional, Loukides, Stelios, additional, Lugogo, Njira L, additional, Papaioannou, Andriana I, additional, Larenas-Linnemann, Désirée, additional, Moore, Wendy C, additional, Perez-de-Llano, Luis A, additional, Rasmussen, Linda M, additional, Schmid, Johannes M, additional, Siddiqui, Salman, additional, Alacqua, Marianna, additional, Tran, Trung N, additional, Suppli Ulrik, Charlotte, additional, Upham, John W, additional, Wang, Eileen, additional, Bulathsinhala, Lakmini, additional, Carter, Victoria A, additional, Chaudhry, Isha, additional, Eleangovan, Neva, additional, Murray, Ruth B, additional, Price, Chris A, additional, and Price, David B, additional

Published
2022
Full Text
View/download PDF

28. Device use errors among patients with asthma and COPD and the role of training: a real-life study

Author

Papaioannou, I, Andriana Bartziokas, Konstantinos Hillas, Georgios Fouka, Evangelia Dimakou, Katerina Kallieri, Maria and Tsikrika, Stamatoula Papadaki, Georgia Papathanasiou, Evgenia Papaporfyriou, Anastasia Apollonatou, Vasiliki and Verykokou, Galateia Mplizou, Myrto Papakosta, Despina and Manali, Effrosyni D. Papiris, Spyridon Loukides, Stelios

Abstract

Background and objectives: Administration of inhaled medication for asthma and COPD is often difficult and incorrect device use is associated with unfavorable outcomes. We aimed to evaluate device use errors in asthma and COPD patients and to associate incorrect use with the patient’s characteristics and medical history. Methods: Demographics and medical history were recorded. The use of each prescribed device was evaluated according to predefined steps. Results: 607 patients (49.9% male, median age (IQR) 63 (51, 70) years performed 663 demonstrations (56 patients were using 2 different types of devices). 51.4% were treated for asthma and 48.6% for COPD. 79.6% of demonstrations were performed using DPIs. Errors were documented on 41.2% of demonstrations and were associated with the type of device, p < 0.001. Elderly patients were less frequently using their devices correctly compared to younger patients, 50.8% vs 62.2%, respectively, p = 0.007. Correct demonstrations were more among asthmatics compared to COPD patients 63.1% vs 54.5%, p = 0.024. Incorrect use was associated with more acute exacerbations in the preceding year [median(IQR), 1(0, 2) vs 1(0, 1)], for incorrect and correct use, respectively, p < 0.001. Upon demonstration, 15.5% of patients have never been trained (i.e., undergone actual demonstrations and observation while using their device) by anyone. Errors occurred more frequently among patients who reported not to be trained compared to those who were trained, 67.0% vs 14.6%, respectively, p Conclusion: Device use errors are common and associated with unfavorable outcomes. Trained patients were more likely to use the device correctly.

Published
2021

29. COVID-19: the day after

Author

Antonogiannaki, Elvira Markela Thomas, Konstantinos Kavatha, Dimitra Manali, Effrosyni D. Konstantonis, Dimitrios and Arkoudis, Nikolaos Achilleas Tsochatzis, Athanasios Kazakou, Pinelopi Grigoropoulou, Sotiria Psarrakis, Christos Paneta, Maria Kallieri, Maria Oikonomopoulou, Chrysanthi Loukidis, Stylianos Antoniadou, Anastasia Papiris, Spyros A.

Published
2021

30. COVID-19: the day after

Author

Antonogiannaki, Elvira Markela, primary, Thomas, Konstantinos, additional, Kavatha, Dimitra, additional, Manali, Effrosyni D., additional, Konstantonis, Dimitrios, additional, Arkoudis, Nikolaos Achilleas, additional, Tsochatzis, Athanasios, additional, Kazakou, Pinelopi, additional, Grigoropoulou, Sotiria, additional, Psarrakis, Christos, additional, Paneta, Maria, additional, Kallieri, Maria, additional, Oikonomopoulou, Chrysanthi, additional, Loukidis, Stylianos, additional, Antoniadou, Anastasia, additional, and Papiris, Spyros A., additional

Published
2021
Full Text
View/download PDF

31. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma

Author

Meghoufel, Z, Cherifi, F, Boukra, A, Terki, F, Porsbjerg, Celeste, Menzies-Gow, Andrew, Tran, Trung, Murray, Ruth, Unni, Bindhu, Audrey Ang, Shi Ling, Alacqua, Marianna, Al-Ahmad, Mona, Al-Lehebi, Riyad, Altraja, Alan, Belevskiy, Andrey, Björnsdóttir, Unnur, Bourdin, Arnaud, Busby, John, Canonica, G. Walter, Christoff, George, Cosio, Borja, Costello, Richard, FitzGerald, J. Mark, Fonseca, João, Hansen, Susanne, Heaney, Liam, Heffler, Enrico, Hew, Mark, Iwanaga, Takashi, Jackson, David, Kocks, Janwillem W.H., Kallieri, Maria, Bruce Ko, Hsin-Kuo, Koh, Mariko Siyue, Larenas-Linnemann, Désirée, Lehtimäki, Lauri, Loukides, Stelios, Lugogo, Njira, Maspero, Jorge, Papaioannou, Andriana, Perez-de-Llano, Luis, Pitrez, Paulo Márcio, Popov, Todor, Rasmussen, Linda, Rhee, Chin Kook, Sadatsafavi, Mohsen, Schmid, Johannes, Siddiqui, Salman, Taillé, Camille, Taube, Christian, Torres-Duque, Carlos, Ulrik, Charlotte, Upham, John, Wang, Eileen, Wechsler, Michael, Bulathsinhala, Lakmini, Carter, Victoria, Chaudhry, Isha, Eleangovan, Neva, Hosseini, Naeimeh, Rowlands, Mari-Anne, Price, David, van Boven, Job FM., Groningen Research Institute for Asthma and COPD (GRIAC), Value, Affordability and Sustainability (VALUE), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)

Subjects
Severe asthma, Biological Products, [SDV]Life Sciences [q-bio], Medizin, Biologics access, Omalizumab, 3. Good health, Biologics eligibility, Biological Therapy, 03 medical and health sciences, BIOLOGICS, 0302 clinical medicine, Prescriptions, 030228 respiratory system, Immunology and Allergy, Humans, ASTHMA, 030212 general & internal medicine, Anti-Asthmatic Agents, ComputingMilieux_MISCELLANEOUS, SEVERE ASTHMA
Abstract

BackgroundRegulatory bodies have approved five biologics for severe asthma. However, regional differences in accessibility may limit the global potential for personalized medicine.ObjectiveTo compare global differences in ease of access to biologics.MethodsIn April 2021, national prescription criteria for omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab were reviewed by severe asthma experts collaborating in the International Severe Asthma Registry. Outcomes (per country, per biologic) were (1) country-specific prescription criteria and (2) development of the Biologic Accessibility Score (BACS). The BACS composite score incorporates 10 prescription criteria, each with a maximum score of 10 points. Referenced to European Medicines Agency marketing authorization specifications, a higher score reflects easier access.ResultsBiologic prescription criteria differed substantially across 28 countries from five continents. Blood eosinophil count thresholds (usually ≥300 cells/μL) and exacerbations were key requirements for anti-IgE/anti–IL-5/5R prescriptions in around 80% of licensed countries. Most countries (40% for dupilumab to 54% for mepolizumab) require two or more moderate or severe exacerbations, whereas numbers ranged from none to four. Moreover, 0% (for reslizumab) to 21% (for omalizumab) of countries required long-term oral corticosteroid use. The BACS highlighted marked between-country differences in ease of access. For omalizumab, mepolizumab, benralizumab, and dupilumab, only two, one, four, and seven countries, respectively, scored equal or higher than the European Medicines Agency reference BACS. For reslizumab, all countries scored lower.ConclusionsAlthough some differences were expected in country-specific biologic prescription criteria and ease of access, the substantial differences found in the current study present a challenge to implementing precision medicine across the world.

Published
2022
Full Text
View/download PDF

32. Device use errors among patients with asthma and COPD and the role of training: a real-life study

Author

Papaioannou, Andriana I., primary, Bartziokas, Konstantinos, additional, Hillas, Georgios, additional, Fouka, Evangelia, additional, Dimakou, Katerina, additional, Kallieri, Maria, additional, Tsikrika, Stamatoula, additional, Papadaki, Georgia, additional, Papathanasiou, Evgenia, additional, Papaporfyriou, Anastasia, additional, Apollonatou, Vasiliki, additional, Verykokou, Galateia, additional, Mplizou, Myrto, additional, Papakosta, Despina, additional, Manali, Effrosyni D., additional, Papiris, Spyridon, additional, and Loukides, Stelios, additional

Published
2021
Full Text
View/download PDF

34. Genotyping and phenotyping of alpha1-antitrypsin deficiency Greek patients under augmentation therapy: a multicenter study

Author

Papiris, Spyros A., primary, Apollonatou, Vasiliki, additional, Tzouvelekis, Argyrios, additional, Tzilas, Vasilios, additional, Karampitsakos, Theodoros, additional, Gerogianni, Irini, additional, Daniil, Zoe, additional, Kolilekas, Lykourgos, additional, Tsaroucha, Aimilia, additional, Papaioannou, Andriana I, additional, Tryfon, Stavros, additional, Markou, Stamatia, additional, Korbila, Ioanna, additional, Vlami, Katerina, additional, Dimakou, Aikaterini, additional, Papanikolaou, Ilias C., additional, Kitrou, Michael, additional, Sardelis, Zafeirios, additional, Stagaki, Eleni, additional, Apollonatos, Gerasimos, additional, Verykokou, Galateia, additional, Kallieri, Maria, additional, Prapa, Athena, additional, Tsilogianni, Zoe, additional, Roussakis, Nikolaos, additional, Antonogiannaki, Elvira-Markela, additional, Papadaki, Georgia, additional, Tsinti, Gerasimina, additional, Speletas, Matthaios, additional, Greulich, Timm, additional, Bouros, Demosthenes, additional, and Manali, Effrosyni D., additional

Published
2020
Full Text
View/download PDF

35. Follow-up of patients with severe eosinophilic asthma receiving mepolizumab for one year in specialized asthma clinics in Greece

Author

Kallieri, Maria, primary, Zervas, Eleftherios, additional, Katsoulis, Konstantinos, additional, Fouka, Evangelia, additional, Porpodis, Konstantinos, additional, Samitas, Konstantinos, additional, Papaioannou, Andriana, additional, Kipourou, Maria, additional, Lyberopoulos, Panagiotis, additional, Gaki, Eleni, additional, Vittorakis, Stylianos, additional, Markatos, Miltiadis, additional, Dimakou, Katerina, additional, Ampelioti, Sevasti, additional, Koukidou, Sofia, additional, Makris, Michail, additional, Ntakoula, Maria, additional, Mitrova, Marija Hadji, additional, Papiris, Spyridon, additional, Tzanakis, Nikolaos, additional, Papakosta, Despina, additional, Bakakos, Petros, additional, and Loukides, Stylianos, additional

Published
2020
Full Text
View/download PDF

36. Devise use errors among patients with asthma and COPD-A real-life study

Author

Papaioannou, Andriana, primary, Bartziokas, Konstantinos, additional, Hillas, Georgios, additional, Fouka, Evangelia, additional, Dimakou, Aikaterini, additional, Kallieri, Maria, additional, Tsikrika, Stamatoula, additional, Papadaki, Georgia, additional, Papathanasiou, Evgenia, additional, Papaporfyriou, Anastasia, additional, Apollonatou, Vasiliki, additional, Verykokou, Galateia, additional, Mplizou, Myrto, additional, Papakosta, Despina, additional, Manali, Effrosyni, additional, Papiris, Spyridon, additional, and Loukides, Stelios, additional

Published
2020
Full Text
View/download PDF

37. Prevalence, distribution and clinical significance of joints, muscles and bones in sarcoidosis: an 18F-FDG-PET/CT study

Author

Papiris, Spyros A., primary, Manali, Effrosyni D., additional, Papaioannou, Andriana I., additional, Georgakopoulos, Alexandros, additional, Kolilekas, Lykourgos, additional, Pianou, Nikoletta K., additional, Kallergi, Maria, additional, Papaporfyriou, Anastasia, additional, Kallieri, Maria, additional, Apollonatou, Vasiliki, additional, Papadaki, Georgia, additional, Malagari, Katerina, additional, Kelekis, Nikolaos L., additional, Pneumatikos, Spyros G., additional, and Chatziioannou, Sofia, additional

Published
2020
Full Text
View/download PDF

38. Follow-up of patients with severe eosinophilic asthma receiving mepolizumab for one year in specialized asthma clinics in Greece

Author

Kallieri, Maria Zervas, Eleftherios Katsoulis, Konstantinos and Fouka, Evangelia Porpodis, Konstantinos Samitas, Konstantinos and Papaioannou, Andriana Kipourou, Maria Lyberopoulos, Panagiotis Gaki, Eleni Vittorakis, Stylianos Markatos, Miltiadis Dimakou, Katerina Ampelioti, Sevasti Koukidou, Sofia Makris, Michail Ntakoula, Maria Mitrova, Marija Hadji and Papiris, Spyridon Tzanakis, Nikolaos Papakosta, Despina and Bakakos, Petros Loukides, Stylianos

Published
2020

39. Genotyping and phenotyping of alpha1-antitrypsin deficiency Greek patients under augmentation therapy: a multicenter study

Author

Papiris, Spyros A. Apollonatou, Vasiliki Tzouvelekis, Argyrios and Tzilas, Vasilios Karampitsakos, Theodoros Gerogianni, Irini and Daniil, Zoe Kolilekas, Lykourgos Tsaroucha, Aimilia and Papaioannou, I, Andriana Tryfon, Stavros Markou, Stamatia and Korbila, Ioanna Vlami, Katerina Dimakou, Aikaterini and Papanikolaou, Ilias C. Kitrou, Michael Sardelis, Zafeirios and Stagaki, Eleni Apollonatos, Gerasimos Verykokou, Galateia and Kallieri, Maria Prapa, Athena Tsilogianni, Zoe Roussakis, Nikolaos Antonogiannaki, Elvira-Markela Papadaki, Georgia and Tsinti, Gerasimina Speletas, Matthaios Greulich, Timm and Bouros, Demosthenes Manali, Effrosyni D. and Papiris, Spyros A. Apollonatou, Vasiliki Tzouvelekis, Argyrios and Tzilas, Vasilios Karampitsakos, Theodoros Gerogianni, Irini and Daniil, Zoe Kolilekas, Lykourgos Tsaroucha, Aimilia and Papaioannou, I, Andriana Tryfon, Stavros Markou, Stamatia and Korbila, Ioanna Vlami, Katerina Dimakou, Aikaterini and Papanikolaou, Ilias C. Kitrou, Michael Sardelis, Zafeirios and Stagaki, Eleni Apollonatos, Gerasimos Verykokou, Galateia and Kallieri, Maria Prapa, Athena Tsilogianni, Zoe Roussakis, Nikolaos Antonogiannaki, Elvira-Markela Papadaki, Georgia and Tsinti, Gerasimina Speletas, Matthaios Greulich, Timm and Bouros, Demosthenes Manali, Effrosyni D.

Published
2020

40. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis

Author

Kallieri, Maria, primary, Zervas, Eleftherios, additional, Katsoulis, Konstantinos, additional, Fouka, Eva, additional, Porpodis, Konstantinos, additional, Samitas, Konstantinos, additional, Papaioannou, Andriana I., additional, Kipourou, Maria, additional, Gaki, Eleni, additional, Vittorakis, Stylianos, additional, Markatos, Miltiadis, additional, Dimakou, Katerina, additional, Ampelioti, Sevasti, additional, Koukidou, Sofia, additional, Makris, Michael, additional, Ntakoula, Maria, additional, Mitrova, Marija Hadji, additional, Glynos, Konstantinos, additional, Antoniou, Katerina M., additional, Gaga, Mina, additional, Tzanakis, Nikolaos, additional, Markopoulou, Katerina, additional, Papakosta, Despoina, additional, Bakakos, Petros, additional, and Loukides, Stelios, additional

Published
2020
Full Text
View/download PDF

42. TERT/TERC mutations in a Greek cohort of suspected genetic pulmonary fibrosis patients

Author

Manali, Effrosyni D. Kannengiesser, Caroline Kolilekas, Lykourgos Korbila, Ioanna Papadaki, Georgia Kallieri, Maria and Giouleka, Paschalina Papaioannou, Andriana I. Tomos, Ioannis P. Stagaki, Eleni Papaporfyriou, Anastasia Karakatsani, Anna and Loukides, Stylianos Kagouridis, Konstantinos Tzilas, Vasileios Tzouvelekis, Argyrios Bouros, Evangelos Antoniou, Katerina Trachalaki, Athina Markopoulou, Aikaterini Daniil, Zoe Fouka, Evangelia Papakosta, Despoina Xyfteri, Areti and Gogali, Athina Konstantinidis, Athanasios Steiropoulos, Paschalis Papanikolaou, Ilias C. Bazaka, Chrysa Charitou, Aggeliki Maniati, Maria Lyberopoulos, Panagiotis Vlami, Katerina Raptakis, Thomas Revy, Patrick Gaga, Mina and Dieude, Philippe Nathan, Nadia Borie, Raphael Boileau, Catherine Bouros, Demosthenes Crestani, Bruno Papiris, Spyros

Published
2018

43. Lung disease caused by non-null ABCA3 mutations: long-term follow-up

Author

Manali, Effrosyni D. Nathan, Nadia Kannengiesser, Caroline and Tomos, Periklis Coulomb-L'Hermine, Aurore Korkolopoulou, Penelope Foukas, Periklis G. Kolilekas, Lykourgos and Kagouridis, Konstantinos Maniati, Maria Argentos, Stylianos and Korbila, Ioanna Tomos, Ioannis P. Roussakis, Nikolaos and Kallieri, Maria Schams, Andrea Griese, Matthias and Tsiligiannis, Theofanis Karakatsani, Anna Loukides, Stylianos and Koutsocheras, Georgios N. Androu, Angeliki Legendre, Marie and Amselem, Serge Borie, Raphael Crestani, Bruno Papiris, Spyros A.

Published
2018

45. Kartagener’s syndrome: A multisystem disease in need of a “multidisciplinary approach” concept.

Author

Verykokou, Galateia, Kallieri, Maria, Mplizou, Myrto, Antonogiannaki, Elvira-Markela, Zarvou, Irene, Moriki, Dafni, Sardeli, Olympia, Apollonatou, Vasiliki, Proikas, Konstantinos, Vrantza, Tereza, Siatelis, Argyris, Tsochatzis, Athanasios, Argentos, Stylianos, Prountzos, Spyridon, Alexopoulou, Efthymia, Dikalioti, Stavroula, Papaioannou, Andriana I., Douros, Konstantinos, Manali, Effrosyni D., and Papiris, Spyros A.

Subjects
*DYSKINESIAS, *BRONCHIECTASIS, *RESPIRATORY infections, *SITUS inversus, *HEARING disorders, *GENETIC mutation, *MUCOCILIARY system
Abstract

Primary ciliary dyskinesia (PCD) is a rare autosomal recessive disorder, with considerable heterogenicity, characterized by a spectrum of corresponding defects in ciliary ultrastructure and/or ciliary function related to genetic mutations effecting motile cilia. The impaired ciliary function impedes mucociliary clearance, which predisposes the patient to upper and lower respiratory tract infections, chronic sinopulmonary infection, development of bronchiectasis and loss of lung function.Recurrent ear infections might lead to hearing loss. Many males with primary ciliary dyskinesia have immobile spermatozoa or dysfunction of cilia in the epididymal duct, leading to infertility.During embryogenesis, nodal cilia, which are motile cilia, determine the correct lateralization of the organs. Dysfunction of these cilia leads to random lateralization and thus situs inversus in patients with primary ciliary dyskinesia. Kartagener’s syndrome describes the classic triad of situs inversus, bronchiectasis and chronic sinusitis due to a congenital reduction or absence of ciliary function. The severity of the disease in adults is highly variable. Herein we present 3 members of a family with PCD developing almost the entire spectrum of manifestations and requiring not only extensive pediatric and adult respiratory medicine management but also a specialized multidisciplinary approach. [ABSTRACT FROM AUTHOR]

Published
2020

46. Skipping a single dose of mepolizumab resulted in significant clinical and functional deterioration.

Author

Papaioannou, Andriana I., Kallieri, Maria, Papiris, Spyridon, and Loukides, Stelios

Subjects
*SYMPTOMS, *ASTHMA, *LUNGS, *BIOLOGICALS, *EOSINOPHILS
Abstract

Therapy with biologics is now the first choice of add on therapy in the management of severe asthma. However, little is known about the consequences of poor adherence to therapy on asthma control and lung function. Here, we report a case of an asthmatic patient with severe eosinophilic asthma whose asthma was ameliorated by mepolizumab use and whose symptoms had worsened, and asthma control was lost after skipping one single dose of the drug. [ABSTRACT FROM AUTHOR]

Published
2020

47. Prevalence, distribution and clinical significance of joints, muscles and bones in sarcoidosis: an 18F-FDG-PET/CT study.

Author

Papiris, Spyros A., Manali, Effrosyni D., Papaioannou, Andriana I., Georgakopoulos, Alexandros, Kolilekas, Lykourgos, Pianou, Nikoletta K., Kallergi, Maria, Papaporfyriou, Anastasia, Kallieri, Maria, Apollonatou, Vasiliki, Papadaki, Georgia, Malagari, Katerina, Kelekis, Nikolaos L., Pneumatikos, Spyros G., and Chatziioannou, Sofia

Published
2020
Full Text
View/download PDF

48. Lung disease caused by non-null ABCA3 mutations: long-term follow-up

Author

Manali, Effrosyni D., primary, Nathan, Nadia, additional, Kannengiesser, Caroline, additional, Tomos, Periklis, additional, Coulomb-L’Hermine, Aurore, additional, Korkolopoulou, Penelope, additional, Foukas, Periklis G., additional, Kolilekas, Lykourgos, additional, Kagouridis, Konstantinos, additional, Maniati, Maria, additional, Argentos, Stylianos, additional, Korbila, Ioanna, additional, Tomos, Ioannis P., additional, Roussakis, Nikolaos, additional, Kallieri, Maria, additional, Schams, Andrea, additional, Griese, Matthias, additional, Tsiligiannis, Theofanis, additional, Karakatsani, Anna, additional, Loukides, Stylianos, additional, Koutsocheras, Georgios N., additional, Androu, Angeliki, additional, Legendre, Marie, additional, Amselem, Serge, additional, Borie, Raphael, additional, Crestani, Bruno, additional, and Papiris, Spyros A., additional

Published
2018
Full Text
View/download PDF

49. TERT/TERC mutations in a Greek cohort of suspected genetic pulmonary fibrosis patients

Author

Manali, Effrosyni D., primary, Kannengiesser, Caroline, additional, Kolilekas, Lykourgos, additional, Korbila, Ioanna, additional, Papadaki, Georgia, additional, Kallieri, Maria, additional, Giouleka, Paschalina, additional, Papaioannou, Andriana I., additional, Tomos, Ioannis P., additional, Stagaki, Eleni, additional, Papaporfyriou, Anastasia, additional, Karakatsani, Anna, additional, Loukides, Stylianos, additional, Kagouridis, Konstantinos, additional, Tzilas, Vasileios, additional, Tzouvelekis, Argyrios, additional, Bouros, Evangelos, additional, Antoniou, Katerina, additional, Trachalaki, Athina, additional, Markopoulou, Aikaterini, additional, Daniil, Zoe, additional, Fouka, Evangelia, additional, Papakosta, Despoina, additional, Xyfteri, Areti, additional, Gogali, Athina, additional, Konstantinidis, Athanasios, additional, Steiropoulos, Paschalis, additional, Papanikolaou, Ilias C., additional, Bazaka, Chrysa, additional, Charitou, Aggeliki, additional, Maniati, Maria, additional, Lyberopoulos, Panagiotis, additional, Vlami, Katerina, additional, Raptakis, Thomas, additional, Revy, Patrick, additional, Gaga, Mina, additional, Dieude, Philippe, additional, Nathan, Nadia, additional, Borie, Raphael, additional, Boileau, Catherine, additional, Bouros, Demosthenes, additional, Crestani, Bruno, additional, and Papiris, Spyros, additional

Published
2018
Full Text
View/download PDF

50. The effects of pulmonary rehabilitation in patients with Combined Pulmonary Fibrosis and Emphysema (CPFE)

Author

Papaioannou, Andriana, primary, Manali, Effrosyni, additional, Lyberopoulos, Panagiotis, additional, Papaporfyriou, Anastasia, additional, Kallieri, Maria, additional, Gyftopoulos, Sotiris, additional, Konstantonis, Dimitrios, additional, Stagaki, Eleni, additional, Papadaki, Georgia, additional, Kostikas, Konstantinos, additional, Spetsioti, Roula, additional, Vogiatzis, Ioannis, additional, Mazioti, Argyro, additional, Loukides, Stelios, additional, and Papiris, Spyros, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results